on Theranexus (EPA:ALTHX)
Publication of the letter to shareholders by Theranexus
On January 8, 2026, Theranexus, a biopharmaceutical company based in Lyon, announced the publication of its letter to shareholders. Specializing in rare neurological diseases, the company continues to share key information about its activities and outlook.
This recently published letter is available on the Theranexus website in the shareholders' section. The company invites its investors to subscribe to receive all its communications.
Theranexus operates in the field of rare diseases with two flagship drugs: TX01 for Niemann-Pick type C disease and Gaucher disease, and Batten-1 for Batten disease. The company is also developing an innovative antisense oligonucleotide platform.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Theranexus news